Blood test for Alzheimer’s

Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer’s Disease Pathology in Both Primary and Specialty Care Settings

August 24, 2026
1:11 pm

BURLINGTON, N.C., Aug. 24, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 and older with signs, symptoms or complaints of cognitive decline. Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings

For many individuals experiencing cognitive decline, evaluation for Alzheimer’s disease often involves multiple tests, care settings and healthcare providers. As blood-based biomarkers for neurological conditions continue to advance, pTau-217 has emerged as a leading biomarker to help clinicians rule in or rule out amyloid pathology in people presenting with symptoms or concerns of cognitive decline. While several pTau-217 assays are commercially available, standardization across care settings remains an important consideration for clinicians. The Elecsys® pTau-217 test provides a single, standardized assay with the same clinically validated cutoffs across primary and specialty care settings, supporting a consistent approach to patient assessment.

Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer’s Disease Pathology in Both Primary and Specialty Care Settings

Sign up for Blog Updates